Manufacturers report positive results on HbA1C and body weight in higher doses of dulaglutide in people with type 2 diabetes

The AWARD-11 trial investigated the safety and efficacy effects of dulaglutide 4.5 mg, 3 mg and 1.5 mg. HbA1c and weight reduction were greater with the 4.5 mg dose (-1.9% and -4.7kg, -1.7% and -4.0 kg, and -1.5% and -3.1kg for 4.5, 3, and 1.5 mg doses respectively).

Source:

Biospace Inc.